May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Intravitreal Triamcinolone (Kenalog) Injection for Macular Edema Associated with Retinal Venous Occlusive Disease
Author Affiliations & Notes
  • R. Mintz
    Ophthalmology and Visual Sciences, WK Kellogg Eye Center/ University of Michigan, Ann Arbor, MI
  • M.W. Johnson
    Ophthalmology and Visual Sciences, WK Kellogg Eye Center/ University of Michigan, Ann Arbor, MI
  • D.N. Zacks
    Ophthalmology and Visual Sciences, WK Kellogg Eye Center/ University of Michigan, Ann Arbor, MI
  • Footnotes
    Commercial Relationships  R. Mintz, None; M.W. Johnson, None; D.N. Zacks, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4573. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Mintz, M.W. Johnson, D.N. Zacks; Intravitreal Triamcinolone (Kenalog) Injection for Macular Edema Associated with Retinal Venous Occlusive Disease . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4573.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate efficacy of intravitreal triamcinolone acetonide (Kenalog) (IVK) injection for treatment of macular edema associated with retinal venous occlusive disease. Methods:A retrospective review of patients with retinal venous occlusive disease and associated macular edema who were treated with intravitreal Kenalog injections since Jan 1, 2003 was performed. A standardized method of IVK injection was used. Type of venous occlusion was determined by clinical examination and fluorescein angiography (FA) obtained on initial presentation. Data recorded includes age, gender, involved eye, pre– and post–treatment visual acuity, and response of edema to treatment as determined by biomicroscopy, fluorescein angiography, and optical computed tomography (OCT). Adverse effects of IVK injection were also reviewed. Results:Fifteen eyes of 15 patients met the inclusion criteria. Age range was 34–78, with a mean age of 64.5 years. The morbidity was branch vein occlusion in 4 patients, hemi–retinal vein occlusion in 2, nonischemic central retinal vein occlusion in 8, and ischemic central retinal vein occlusion in 1. Time from diagnosis to treatment ranged from 1 month to 2 years. Follow–up after IVK injection ranged from 1 week to 8 months. Thirteen (87%) of 15 eyes had clinically evident improvement in macular edema. Ten (66%) of 15 eyes showed improvement in visual acuity of 3 or more lines. Of the remaining eyes, four were stable and one had worsening visual acuity. Most (80%) of the eyes that experienced visual improvement did so by their 1 week post–operative visit. Three eyes required re–injection during the follow–up period, though only one responded with visual improvement after the re–injection. Complications of IVK injection included increased intra–ocular pressure (IOP) requiring further treatment in 7 (47%) eyes. Conclusions:Our data suggests that IVK injection may play an important role in the treatment of macular edema associated with retinal venous occlusive disease. Further clinical research is needed to determine what factors may be predictive of visual improvement following this procedure.

Keywords: vascular occlusion/vascular occlusive disease • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×